ANAVEX-LOGO_JPG

Anavex Life Sciences Corp (OTCMKTS:AVXL)’s ANAVEX 2-73 Prevents Mitochondrial Dysfunction

Anavex Life Sciences Corp (OTCMKTS:AVXL) announced that it is encouraged by the results of a research report published in peer-reviewed scientific journal titled as Frontiers in Cellular Neuroscience. The report revealed that the company’s candidate ANAVEX 2-73 could prevent Alzheimer in addition to treating symptoms.

The details

Anavex Life Sciences Corp (OTCMKTS:AVXL)’s Anavex 2-73 is said to prevent mitochondrial dysfunction. It blocks apoptosis and oxidative stress in Alzheimer. Mitochondrial damages are main factors leading to AD. They are noticed before memory loss and amyloid-beta plaques in Alzheimer’s patients and transgenic mice. By reducing key AD hallmarks and preserving mitochondrial functionality, ANAVEX 2-73 has the potential to stop, prevent, reverse or slow the disease.

The experts view

Tangui Maurice, Ph.D., CNRS Research Director, stated that the authors have provided evidence that the neuro-protective function of sigma-1 receptor agonists involves mitochondrial protection in the AD group. The drug candidate of Anavex Life Sciences Corp (OTCMKTS:AVXL) efficiently met its objective of protecting mitochondria against amyloid-beta. It resulted in an impairment of mitochondrial respiration that is the energy producing course within the cell. The resultant oxidative stress and mitochondrial dysfunction are main hallmarks of Alzheimer’s pathology.

The management view

Christopher U. Missling, PhD, the President and CCEO of Anavex Life Sciences Corp (OTCMKTS:AVXL), said that the management is encouraged by the study results, which highlights the potential ability of ANAVEX 2-73 to protect neurons from amyloid-beta overproduction and oxidative stress. The two problems can result in toxicity and follow-on damage that can be now prevented with the drug. It has ability to prevent the onset of Alzheimer.

The approach

Missling further said that Anavex Life Sciences Corp (OTCMKTS:AVXL)’s approach targets disease’s upstream and clearly blocks disease hallmarks. It is a promising approach. The new results strengthen company’s drug candidate potential in Alzheimer disease. It can act as a preventative drug. The report was jointly prepared by Tangui Maurice, Valentine Lahmy, Vanessa Villard, Romain Long and Didier Morin from the University of Montpellier.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 traders350.com. All RIGHTS RESERVED.